Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220864 | 0.83 | NPC1 (0.32) | NPC1MAPTRAB9A | |
| SCHEMBL7220676 | 0.80 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7214245 | 0.80 | CRHR1 (0.64) | CRHR1 | |
| SCHEMBL7219810 | 0.78 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL7219601 | 0.78 | CRHR1 (0.41) | CRHR1ALDH1A1POLBNPC1MAPT | |
| SCHEMBL7219771 | 0.77 | CRHR1 (0.37) | CRHR1ALDH1A1 | |
| SCHEMBL7219767 | 0.76 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL7219467 | 0.76 | CRHR1 (0.45) | CRHR1ALDH1A1 | |
| SCHEMBL7219574 | 0.75 | CRHR1 (0.55) | CRHR1ALDH1A1 | |
| SCHEMBL7220849 | 0.74 | CRHR1 (0.49) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | claimed |
| US-6589958-B1 | Treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885ALDH1A1 894/4885POLB 2627/4885 |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885ALDH1A1 894/4885POLB 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.